The purpose of this study was to test the direct applicability of CEDIA DAU urine immunoassays to serum or whole blood. The performance of the urine assays for sensitive screening of amphetamines (AMP), benzoylecgonine (BZE), benzodiazepines (BENZ), methadone (MET), opiates (OPI), and tetrahydrocannabinol carboxylic acid (THCCOOH) was evaluated on the BM/Hitacbi 911 analyzer with unpretreated serum and whole blood. The limit of detection was 0 ng/mL for all tests. Cutoff values were set from 10 to 40 ng/mL for the different assays. The assays were found to be linear between the following concentrations: AMP 0-2500 ng/mL, BZE 0-1200 ng/mL, BENZ 0-1600 ng/mL, MET 0-600 ng/mL, OPI 0-720 ng/mL, and THCCOOH 24-60 ng/mL. Precision results (within run) for different concentrations were as follows: AMP 3.1-5.7%, BZE 2.4-6.6%, BENZ 4.3-8.0%, MET 2.0-5.5%, OPI 2.8-7.6%, and THCCOOH 1.4-2.4%. Between-run results were as follows: AMP 8.7-15.5%, BZE 6.4-7.5%, BENZ 8.2-15.8%, MET 2.7-5.1%, OPI 4.3-11.2%, and THCCOOH 2.6-7.4%. Sensitivity, specificity, and comparison of CEDIA semiquantitation with GC-MS quantitative results were performed on 500 original serum and whole blood samples. The data provided sufficient documentation to use the CEDIA urine-screening technique without any adaptation as a sensitive serum/whole blood screening for BZE, BENZ, MET, OPI, and THCCOOH. Se(um screening for amphetamines is not sensitive enough in the unchanged urine mode. It will require some adaptation to a serum mode (probably a higher sample volume [BM/Hitacbi 911] combined with protein precipitation of the sample).
Introduction
The widespread use of immunoassay technique for the screening of drugs of abuse in urine is based on its fast performance and good sensitivity. However, in many cases, immunological analysis of blood and serum is required, for example, when no urine sample is available. Depending on the technology of the manufacturer (FPIA, EIA, KIMS) and the measured wavelength of the analyzer, protein content or turbidity of serum or hemoglobin of whole blood samples may result in high background absorbance levels (1) or error messages (2) . Therefore, numerous *Author to whom correspondence should be addressed.
efforts have been made to adapt the urine immunoassays to serum or whole blood. Indirect application for EMIT or TDx/ADx was achieved by protein precipitation with methanol (3, 4) , acetone (5) , trichloroacetic acid (6), or zinc sulfate (2) . Other possibilities are the extraction of the blood sample (7, 8) or simple dilution with saline (9) . Disadvantages of these methods are that they are time consuming and probably result in a loss of sensitivity. This is of special interest when the result of the screening is required urgently, especially for clinical cases. Another problem specific to Germany is that suspected impaired car drivers or other road users can refuse to supply a urine sample but not a blood specimen. As a consequence, the number of cases in which only a blood sample (and no urine sample) is available for analysis is steadily increasing. The blood-sample Vacutainer tubes used by the police contain sodium or potassium fluoride. Because of these salts, blood samples for the analysis for drugs of abuse are more or less hemolyzed. Concerning blood samples, another important aspect is that in many cases only very limited sample material is available. Especially for forensic (impaired drivers, criminals) and clinical cases, it is necessary to detect very low concentrations of drugs of abuse. A procedure that can show sensitively which test parameters require a confirmation method saves time and assists in getting analytic data of high quality from a small quantity of sample, sometimes only 1 mL of blood.
As a first step, we tested whether the high protein content of serum samples interferes with the cloned enzyme donor immunoassay (CEDIA) and whether it is necessary to perform a special calibration with serum calibrators that are in lower concentration ranges than those supplied by the manufacturer. To do this, we selected the opiate (OPI) and benzoylecgonine (BZE) assays as test parameters. Serum and urine blanks were spiked with morphine or BZE and measured with the urine standard calibration mode (as recommended by the manufacturer) and with a self-spiked serum calibration with lower concentrations. Subsequently, hemolytic whole blood and acetone-precipitated serum samples were measured. This pretest showed the successful applicability of CEDIA DAU for the direct measurement of opiates and BZE in serum and whole blood. Therefore, a systematic evaluation for all test parameters mentioned was begun. Reagents All solvents were of reagent-grade quality. CEDIA immunoassay reagents were supplied by Boehringer Mannheim (Mannheim, Germany). Reagents for the ADx were supplied by Abbott GmbH (Wiesbaden, Germany). Reagents and test tubes for RIA were supplied by Biermann (Bad Nauheim, Germany). Measurements were done on a y-counter (Berthold, Isernhagen, Germany). All procedures for the preparation of the immunoassay reagents were the same as those recommended by the manufacturer for the analysis of urine. The CEDIA test has two multiurine controls (for methamphetamine, BZE, morphine, nitrazepam, and methadone) and two controls (25 ng and 50 ng/mL) for THCCOOH which were used to check the accuracy 
Materials and Methods

Experimental Pretest
Serum and urine blank samples were spiked with morphine (10, 50, 100, 200, 300, 500, 800, 1000, and 2000 ng/mL) or BZE (10, 50, 100, 200, 300, 500, 600, and 800 ng/mL) and measured with the urine standard calibration mode (as recommended by the manufacturer: BZE 300, 2000, and 5000 ng/mL; OP1300, 800, and 2000 ng/mL) and subsequently with a self-spiked serum calibration with lower concentrations (BZE 200, 500, 1000 ng/mL; OPI 150, 300, 500 ng/mL). Drug-free serum and urine specimens were obtained from laboratory personnel. After these measurements an acetone precipitation was performed for the spiked serum samples as follows: aliquots of 500 tJL were added dropwise to 1 mL acetone, then vortex mixed for I rain and centrifuged at 4000 rpm for 5 rain. The clear supernatant was evaporated under nitrogen and reconstituted in 500 IJL of ADx buffer solution. The reconstituted sample was again measured by BM/Hitachi 911 analyzer and compared with direct serum measurements. Hemolyzed blood samples were spiked and run like serum samples to see if red color interfered with the test. The instrument settings were the same as the settings for the urine specimens recommended by the manufacturer. The only exception was the THCCOOH assay. Routinely, a cutoff of 20 ng/mL instead of 25 ng/mL is used.
Limit of detection, cutoff, and precision
The limit of detection was calculated by adding three standard deviations to the mean of 21 replicates of a blank serum. Because of the necessary low limit of detection, cutoffs were set as follows: AMP, 20 ng/mL; BZE, 10 ng/mL; BENZ, 10 ng/mL; MET, 40 ng/mL; OPI, 10 ng/mL; THCCOOH, 10 ng/mL. For within-run precision, three controls of a low, medium, and high serum concentration were assayed in 21 replicates. Between-day precision was determined by assaying each of the low, medium, and high control in three replicates per day for 21 consecutive days. The low, medium, and high concentrations are shown in Table I . Linearity was analyzed by 11 dilution steps of a high concentration, starting 10% over the assay range.
Immunoassays (CEDIA, FPIA, RIA) Five hundred serum or whole blood hemolyzed samples from clinical poisonings or impaired drivers were centrifuged and run on the BM/Hitachi 911 analyzer with CEDIA DAU reagent under the same conditions as urine samples. Following this initial testing CEDIA-negative samples (under the cutoff) were precipitated with acetone as described with the only difference being that 20 IJL of isopropanolic HCI was added before evaporation. The reconstituted samples were tested using the ADx analyzer and complete ADx reagent. Pretests with spiked acetone precipitated samples showed the ADx to have a nearly equal or partially better sensitivity (amphetamines) than CEDIA with the exception of the benzodiazepine test. Therefore, we used it as a method for cross checking CEDIA-negative samples. Additionally, CEDIA-negative samples were retested by RIA for morphine and by HPLC for benzodiazepines. Positive samples by either screening assay with a displayed drug concentration higher than the CEDIA cutoffs were selected for confirmation by gas chromatography-mass spectrometry (GC-MS). Radioimmunoassay (RIA) was performed according to the manufacturers instruction. A five-point standard curve from 2.5 to 250 ng/mL was generated. The cutoff positive calibrator was 5 ng/mL. The correlation coefficient for each standard curve was 0.998 or greater.
GC-MS
Quantitative GC-MS was performed on 91, 102, and 21 samples positive for BZE, opiates, and methadone, respectively, as described elsewhere (10) and on 16 samples positive for amphetamines as described elsewhere (11) . Quantitative GC-MS was performed on 71 samples positive for THCCOOH as follows:
. _jz. 10 ng and 20 ng of the deuterated standards (THC-d3, THC-COOH-d3) were added to 1 mL of centrifuged serum and transferred to an RP18 column (Baker) conditioned with 1 mL methanol and 1 mL distilled water. The column was then washed consecutively with 2 mL distilled water, 2 mL acetic acid (0.25 mol/L), and 2 mL distilled water; dried by passing air through it for 10 min; and subsquently centrifuged for 10 min (4000 rpm). Adsorbed drugs of abuse were eluted with 3 x 0.5 mL acetone. The eluent was evaporated to dryness under a stream of nitrogen at 50~ The residue was reconstituted with 150 IJL tetrabutylammonia hydroxide/dimethyl sulfoxide (2:98, v/v). After 2-rain incubation at room temperature, 50 IJL iodomethane was added and the solution vortex mixed. The reaction was stopped after an additional 5 rain with 350 IJL HCI (0.1 tool/L). Extraction of the methylated products followed twice with 2 x I mL isooctane for 1 rain. After centrifugation the organic phases were decanted into a clean tube, dried under nitrogen, and reconstituted in 50 IJL isooctane. A 1-1JL quantity of the sample was injected into the same GC-MS system as described for opiates. The temperature was programmed from 100 (3-min hold) to 180~ at 30~
and to 290~ at 10~ (8-rain hold). The MS detected the following ions of the methylated products in selected ion monitoring mode: THC-d3 316/331,THC 313/328, THCCOOH-d3 316/360/375, and THCCOOH 313/357/372.
Standard curves were generated using a six-point standard curve from 10 to 500 ng/mL for amphetamine, BZE, cocaine, codeine, dihydrocodeine, MBDB, MDA, MDEA, MDMA, methamphetamine, morphine, and methadone. Six-point curves from 1 to 50 ng/mL were generated for THCCOOH and THC. The detection limits were 0.5 ng/mL for THCCOOH and THC; 5 ng/mL for benzoylecgonine, codeine, dihydrocodeine, and morphine; and 10
Table V. Results of 16 Blood Samples Analyzed by CEDIA and GC-MS for Amphetamines
GC-MS
ng/mL for amphetamine, cocaine, MBDB, MDA, MDEA, MDMA, methamphetamine, and methadone. The correlation coefficient for each standard curve generated was 0.998 or greater.
High-performance liquid chromatography (HPLC)
Quantitative HPLC was performed on 47 samples positive for benzodiazepines and for cross checking of the 453 benzodiazepine-negative samples. Five-hundred nanograms of the internal standard papaverine was added to 1 mL of centrifuged serum. The pH was adjusted to pH 8-9, 1 mL K2HPO 4 buffer (pH 8-9) was added, and the solution was vortex mixed for 5 min. After centrifugation, the supernatant was transferred to an RP18 (Baker) column conditioned with 2 mL methanol and 2 mL distilled water. The column was then washed consecutively with 2 x I mL distilled water and dried by passing air through for 10 min. Adsorbed drugs of abuse were eluted with 3 x 0.5 mL methanol. The eluent was evaporated to dryness under a stream of nitrogen at 50~ The residue was reconstituted in 50 pL methanol. HPLC analysis: a 20-1JL quantity of the sample was injected into the HPLC system. Instrumentation: LDC/Milton Roy SpectroMonitorTMD detector, pump: TSP Constametric, wavelength 220 nm. The system was equipped with a RP18 LiChrospher| column, solvent system: (4.80 g H3PO 4 + 6.66 g K2HPO 4 in 1 L distilled water, adjusted to pH 2.3) + 458.8 g acetonitrile. Flow rate was 1 mL/min.
Standard curves were generated using a six-point standard curve from 40 to 500 ng/mL for nitrazepam, diazepam, oxazepam, nordazepam, temazepam, bromazepam, midazolam, and clobazam. Six-point curves from 10 to 50 ng/mL were generated for clonazepam, flunitrazepam, and tetrazepam. 
Results and Discussion
Pretest Figures 1 and 2 show the results of spiked blank serum measured with urine or serum calibration and after protein precipitation. Acetone-precipitated samples gave the same results as unpretreated serum for benzoylecgonine and 10-30% lower results for morphine. The use of the serum calibration curve or the standard urine calibration curve gave approximately the same results. For that reason and ease of use, the standard urine calibration curve was selected for further determinations. Figures 3 and 4 show that red color due to hemoglobin does not interfere with the test. However, it has to be noted that high viscosity of blood samples (e.g., postmortem blood) may cause problems for the pipette station of the Ioumal of Analytical Toxicology, Vol. 23, July/August 1999 BM/Hitachi 911 analyzer. A precipitation step is thus recommended for very viscous samples to be on the safe side. Spiked blank urine samples delivered the same results as spiked serum samples. Thus, serum proteins do not interfere with the test, and direct measurement without any preliminary treatment of serum samples is therefore possible, in principle. After these successful pretests, the main study was begun. 
Limit of detection and precision
In all assays tested the limit of detection was 0 ng/mL. This result was corroborated by all the following measurements. Whereas urine blank measurements (i.e., dependent on turbidity, bacterial contamination, etc.) often give threshold displays of 10-30 ng/mL and even as high as 100 ng/mL, serum measurements show distinctively lower thresholds, most often a zero display. Of course, this is dependent on the quality of the serum sample too. Table I lists the spiked low, medium, and high serum concentrations, and Table II shows the mean concentrations with GC-MS CEDIA. Table III lists the average within-run and between-day precision for CEDIA. For the low-THCCOOH concentration of 15 ng/mL, no coefficient of variation (CV%) is given. This is because the display for about half of the samples showed 0 ng/mL as a result. However, in real samples, a combination of different cannabinoids that crossreacts with the antibody is present. As can be seen in Table IV 
Linearity
Figures 5A-F show the results of the linearity test for the different groups. The assays were found to be linear between the following concentrations: AMP 0-2500 ng/mL, BZE 0-1200 ng/mL, BENZ 0-1600 ng/mL, MET 0-600 ng/mL, OPI 0-720 ng/mL, and THCCOOH 24-60 ng/mL. The pretests have already shown that linearity begins at 10 ng/mL for opiates and benzoylecgonine, respectively. Because of the very low limits of detection, very low cutoffs from 10 to 40 ng/mL were selected as follows: AMP 20 ng/mL, BENZ 10 ng/mL, MET 40 ng/mL, OPI 10 ng/mL, and THCCOOH 10ng/mL.
Method comparison
Comparison of GC-MS quantitative and CEDIA semiquantitative results are shown in Tables  IV-IX 
Amphetamines
Results for 16 blood samples analyzed for amphetamines by CEDIA and GC-MS are shown in Table V . Referring to the cutoffof20 ng/mL, 13 samples were false negatives. These results show that the amphetamine urine test is not suitable for serum testing without adaptation. One reason is the lower cross-reactivity of commonly used amphetamine derivatives such as MDMA (69%), MDEA (21%), and MBDB (60%) compared with methamphetamine. Another reason is that serum proteins may cause interferences in this test, which is not the case with other assays. This became evident when the sample volume was increased on the BM/Hitachi 911 analyzer from 3 IJL (as recommended for the urine tests) to 18 IJL to increase sensitivity for amphetamine detection. With the so-adapted calibration, spiked urine concentrations of 150 ng methamphetamine/mL were shown as Display CEDIA (ng/mL) e 9 9 e.e 9 9 9149 500 1.000 1.500 2.000 2.500 GCMS (ng/mL) Display CEDIA (ng/mL) B 3,~ 3 .000 ~-y 2.000 t.500
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x-y 400 , -MS  CEDIA  GC-MS   600  320  460  270  870  210  250  315  275  177  394  100  487  80  534  200  303  390  246  288  290   310  222  496  170  276  314  246  385  387  461  360   360  300  360  370  266  160  90  120  310  300   200 Table IX 146 ng/mL, whereas the same concentration in spiked serum was shown as only 20 ng/mL. Lower concentrations than 150 ng methamphetamine/mL could not be detected in serum at all, whereas detected urine concentrations went down to 10 ng/mL (results not shown). It will therefore be necessary to adapt the urine test for a sensitive detection of amphetamines in serum. A combination of enhancement of sample volume on the BM/Hitachi 911 analyzer and preliminary treatment of the sample (protein precipitation) is very promising. Amphetamine precipitation with organic solvents is problematic because of the loss of the very volatile amphetamines during the drydown step of the organic supernatant. Addition of methanolic HC1 prevents this amphetamine loss, but it also causes a loss of about 30% of cannabinoids (12) . However cannabinoids can be directly measured (as will be shown later in this paper).
A good alternative for organic solvents is the precipitation by zinc sulfate. This method was shown to work for sensitive determination (cutoff 25 ng/mL) of methamphetamine with TDx (2), but we did not test it here.
BZE
In contrast to the amphetamines, BZE could be detected at very low concentrations. All immunological positive samples (at a cutoff of 10 ng/mL) could be confirmed by GC-MS. Two false negatives were detected by GC-MS with results of 155 ng BZE and 1100 ng BZE/mL, respectively. These two samples were extremely hemolytic and viscous. As we showed in the pretest, red color does not interfere with the assay. It was the viscosity of the samples that made it difficult for the pipette to get enough sample volume. Probably, in each case, no sample got into the assay at all. Therefore, blood samples have to be controlled for their viscosity before running the assays. Highly viscous samples should be centrifuged or treated with acetone or both. The linearity test ( Figure 5B) showed the CEDIA BZE assay to be linear from 0 ng/mL to 1200 ng/mL. All assays showed that at low concentrations the linearity is best (with exception for THCCOOH). The good correlation of GC-MS and CEDIA results (Table VI, Figure 6A) show that a sensitive semiquantitative BZE detection is possible in serum and whole blood without any adaptation.
Benzodiazepines
Direct and sensitive benzodiazepine measurement is also possible in serum. No false positives and no false negatives could be detected. This is probably because the CEDIA benzodiazepine assay does not use a monoclonal antibody like the other CEDIA tests (13) (8) showed that the FPIA urine assay was -not able to detect 70 ng of several benzodiazepines -after serum extraction with butyl chloride. Table X  - shows that the CEDIA test is able to detect 10 ng/mL for some benzodiazepines. Therefore, it 32o appeared necessary to check the immuno-nega-803 tives by the more sensitive HPLC method, but no _ false negatives were discovered. The use of polyclonal antibodies is very good for the specific and sensitive detection of benzodiazepines, and this is the main point when doing an immunological screening. Because of the use of polyclonal antibodies the correlation of HPLC to CEDIA semiquantitative results must be very noisy when more than one benzodiazepine and metabolites are present in the sample (Tables VII and X) .
Methadone
All samples positive for methadone could be confirmed by GC-MS. Correlation of CEDIA semiquantitation with GC-MS was low (Table VIII and Figure 6C ). We did not distinguish between d-and /-methadone in the study. The addition of a fifth, very low calibrator to the standard curve may improve the correlation (communication of Boehringer Mannheim). Patients who receive methadone for substitution show usually blood levels of 50-400 ng/mL. A cutoff of 40 ng/mL will therefore be low enough to detect this.
Opiates
Opiate detection with CEDIA was very specific and sensitive in serum and blood. All positives were confirmed by GC-MS. Three false negatives were found at very low (see Cases ]9, 25, and 82, Table IX) concentrations. Two of these "false negatives" contained no morphine at all but did contain morphine glucuronide (cross-reactivity of the opiate test for morphine-3-glucuronide is 81%). As already shown in the pretest (Figure 2 ), CEDIA has good linearity at low concentrations. Semiquantitative CEDIA results were usually higher than GC-MS results even when the different cross-reactivities of codeine, morphine, morphine glucuronide, and dihydrocodeine were taken into consideration (Table IX, Figure 6B ).
THCCOOH
For THCCOOH, all CEDIA results higher than 10 ng/mL could be confirmed by GC-MS. Linearity could be detected from 24 ng/mL up to 60 ng/mL, but GC-MS results did not correlate with CEDIA semiquantitation (Table IV, Figure 6D ). Similar results for THCCOOH CEDIA assay were found by Cagle et al. (12) after acetone pretreatment of blood. With a cutoff of 25 ng/mL, they found FPIA semiquantitation to show a much better correlation with results of GC-MS than CEDIA. Sensitivity differences of both tests were not tested. Other authors chose a 25-ng cutoff for FPIA after acetone precipitation to get presumptive positives (< 2 ng THC/mL) by GC-MS (16) . Although there is almost no correlation between CEDIA semiquantitation and GC-MS results, all CEDIA-positives could be confirmed by GC-MS. The low correlation is due to the CEDIA assay's cross-reactivity to other cannabinoids and metabolites. Therefore, very sensitive detection of cannabis misuse in unpretreated serum/blood is possible for concentrations far below 2 ng THC/rnL.
Conclusions
The data provided sufficient documentation to use the CEDIA screening technique without any adaptation as a very reliable method to detect analytically low but toxic concentrations of BZE, BENZ, MET, OPI, and THCCOOH in serum or whole blood without any pretreatment of the samples and without any changes at the BM/Hitachi 911 analyzer for routine urine measurements. Serum screening for amphetamines is not sensitive enough in the unchanged urine mode. It will require some adaptation to a serum mode (probably a higher sample volume [BM/Hitachi 911] combined with protein precipitation of the sample). This procedure saves time and assists in economic use of very small sample specimens.
